[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"antiretroviral-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:antiretroviral-therapy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,85],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100645068","phase-4-effectiveness-and-safety-of-darunavircobicistat-plus-lamivudine-compared-with-darunavircobicistat-plus-tenofovir-alafenamideemtricitabine-in-virologically-suppressed-people-living-with-hiv-at-24-and-48-weeks-of-follow-up-100645068",false,"NCT07678268","Effectiveness and Safety of Darunavir\u002FCobicistat Plus Lamivudine Compared With Darunavir\u002FCobicistat Plus Tenofovir Alafenamide\u002FEmtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-up","TLALOC-2","Inclusion Criteria:\n\n* Virologically suppressed men living with HIV, transitioning from a DRV\u002Fc (800 mg\u002F150 mg) + TDF\u002FFTC (300 mg\u002F200 mg) regimen for at least 48 weeks prior to the study\n* Viral suppression for 48 weeks prior to the study\n* Agree to participate in the study by signing a written informed consent form\n* Age ≥18 years\n* Glomerular filtration rate (GFR) by CDK-EPI ≥60 mL\u002Fmin\n* Beneficiaries of the Mexican Social Security Institute (IMSS) treated at the Infectious Diseases Hospital of the \"La Raza\" National Medical Center\n\nExclusion Criteria:\n\n* Withdrawal of informed consent\n* Loss of coverage\n* Failure to attend sample collection within the required timeframe","MALE","18 Years",{"count":19,"type":20},78,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","A single-center, open-label, randomized pilot clinical trial between March 2025 and March 2026 at the Hospital de Infectología \"La Raza\" National Medical Center in Mexico City. Eligible participants were adult males (≥18 years) with HIV-1 infection who had maintained virological suppression (HIV-1 RNA \\\u003C50 copies\u002FmL) for 48 weeks on either DRV\u002Fc + 3TC or DRV\u002Fc + TDF\u002FFTC prior to enrollment (TLALOC-1 trial), and had an estimated glomerular filtration rate (eGFR) by CKD-EPI ≥60 mL\u002Fmin\u002F1.73 m². The primary endpoints were virological efficacy and safety at 24 weeks.",[26,27,28],"HIV Infection","Antiretroviral Therapy","Lentivirus Infections",[30,31,32,33,34],"HIV infection","antiretroviral therapy","two drugs regimen","renal safety","neuropsychiatric adverse events","RECRUITING","2026-06-25",{"date":38,"type":39},"2026-07-01","ACTUAL",{"date":41,"type":39},"2025-07-10",{"date":43,"type":20},"2026-12-10",{"name":45,"class":46},"Instituto Mexicano del Seguro Social","OTHER_GOV",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":57,"minAge":17,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":21,"phases":60,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":4},"100641318","intestinal-tissue-resident-memory-t-cells-and-hiv-1-persistence-during-antiretroviral-therapy-100641318","NCT07656077","Intestinal Tissue-Resident Memory T Cells and HIV-1 Persistence During Antiretroviral Therapy","Intestinal Tissue-Resident Memory T Cells in HIV-1 Infection: Mechanisms Involved in Their Depletion and Role in Viral Persistence During Antiretroviral Therapy","ANRSGALT-2","I - Inclusion criteria\n\n1 - Group 1: People Living With HIV-1\n\n* Age ≥ 18 years\n* Documented HIV-1 infection\n* Continuous suppressive antiretroviral therapy initiated during chronic infection for at least 12 months\n* Plasma HIV-1 RNA ≤ 50 copies\u002FmL for at least 6 months under ART (one isolated blip ≤ 200 copies\u002FmL allowed)\n* Blood CD4+ T-cell count ≥ 350 cells\u002Fmm³\n* Clinically indicated colonoscopy independent of the research protocol\n* Affiliation with a social security system\n* Written informed consent obtained before any study-specific procedure\n\n  2- Group 2: HIV-Seronegative Controls\n* Age ≥ 18 years\n* HIV-seronegative status\n* Clinically indicated colonoscopy independent of the research protocol\n* Affiliation with a social security system\n* Written informed consent obtained before any study-specific procedure\n\nII - Exclusion Criteria\n\n1. Group 1: People Living With HIV-1\n\n   * HIV-2 infection\n   * Inflammatory bowel disease (Crohn's disease or ulcerative colitis) or celiac disease\n   * Platelet count \\\u003C 50 G\u002FL or uncorrectable coagulation disorders contraindicating biopsies\n   * Decompensated cirrhosis\n   * History of lymphoma\n   * Participation in an HIV vaccine or immunotherapy study\n   * Pregnant or breastfeeding women\n   * Participation in another clinical study with an ongoing exclusion period\n   * Vulnerable individuals, including minors, individuals under guardianship, or persons deprived of liberty\n2. Group 2: HIV-Seronegative Controls\n\n   * HIV-1 or HIV-2 infection\n   * Refusal to undergo HIV serology testing\n   * Inflammatory bowel disease (Crohn's disease or ulcerative colitis) or celiac disease\n   * Platelet count \\\u003C 50 G\u002FL or uncorrectable coagulation disorders contraindicating biopsies\n   * Decompensated cirrhosis\n   * History of lymphoma\n   * Pregnant or breastfeeding women\n   * Participation in another clinical study with an ongoing exclusion period\n   * Vulnerable individuals, including minors, individuals under guardianship, or persons deprived of liberty",true,"ALL",{"count":59,"type":20},30,[61],"NA","The study aims to better characterize intestinal tissue-resident memory T cells (TRM) in people living with HIV-1 receiving suppressive antiretroviral therapy (ART). TRM cells are key components of tissue immunity and may contribute to HIV-1 persistence within the intestinal mucosa, a major viral reservoir. The phenotypic, transcriptomic, and functional characteristics of intestinal CD4+ and CD8+ TRM cells, their susceptibility to HIV-1 infection, and their potential role as viral reservoirs will be investigated. Blood samples and additional colonic biopsies obtained during routine clinically indicated colonoscopy will be collected from HIV-1-infected participants and HIV-seronegative controls.",[64,65,27],"HIV-1 Infection","HIV Reservoir",[67,68,69,70,71,72,73,74],"HIV-1","Tissue-Resident Memory T Cells","Viral Reservoir","ART","Intestinal Mucosa","Mucosal Immunity","CD4 T Cells","HIV Persistence","NOT_YET_RECRUITING","2026-06-14",{"date":78,"type":39},"2026-06-18",{"date":80,"type":20},"2026-08-01",{"date":82,"type":20},"2030-07-31",{"name":84,"class":46},"ANRS, Emerging Infectious Diseases",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":57,"minAge":17,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":95,"conditions":96,"keywords":99,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":47},"100642411","impacts-of-hiv-treatment-regimens-on-archived-drug-resistance-100642411","NCT07643948","Impacts of HIV Treatment Regimens on Archived Drug Resistance","Impact of Antiretroviral Therapy (ART) Switch on Archived HIV-1 Drug Resistance in Virally Suppressed Patients: A Prospective Cohort Study","Inclusion Criteria:\n\n* Patients living with HIV who are (a) aged 18 or above, (b) on antiretroviral therapy, (c) has viral load \\\u003C20 copies\u002FmL at 2 time points for ≥6 months, (d) planning regimen switch.\n* Patients for inclusion in the control group meet the same criteria (a) but they are not planned for switch. Controls include patients with low level viremia (LLV) as defined as ≥2 consecutive viral load level between 21 and 200 copies\u002FmL in the preceding 2 years.\n\nExclusion Criteria:\n\n* Patients living with HIV who (a) are pregnant, (b) have virologic failure, (c) are suffering from concurrent opportunistic infections, (d) are prisoners , (e) are unable to give consent, and (f) have mental illnesses.",{"count":93,"type":20},420,"OBSERVATIONAL","The study aims to determine the prevalence of drug resistance mutation (DRM) in virally suppressed HIV infection, and the impacts of regimen change and the presence of low level viremia. Adults living with HIV infection on antiretroviral therapy (ART) with full viral suppression would be recruited. Cases are patients planning for regimen switch, while controls are those with and without low level viraemia (LLV) not planned for switch. Blood samples would be collected before and after switch. Sequencing would be performed to identify DRM present in HIV-1 proviral DNA.",[97,27,98],"HIV -1 Infection","Drug Resistance, Microbial",[31,100,101,102,103,30],"regimen switch","archived resistance","low level viremia","proviral DNA","2026-06-10",{"date":106,"type":39},"2026-06-12",{"date":108,"type":39},"2025-10-01",{"date":110,"type":20},"2029-12-31",{"name":112,"class":113},"Chinese University of Hong Kong","OTHER"]